

Re Elmat
HJB
13-16-02
DT

Atty. Dkt. No. 033236/0115

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Steve Qi et al.

Title: CONTROLLED RELEASE
FORMULATION COMPRISING
GNRH-II

Appl. No.: 09/857,115

HAND-DELIVERED TO:
Ms. Vonda Wallace

Filing Date: 06/01/2001

Examiner: Unassigned

Art Unit: Unassigned

SECOND PRELIMINARY AMENDMENTCommissioner for Patents
Box New Application-
Washington, D.C. 20231

Sir:

Please disregard the Preliminary Amendment filed December 26, 2001, and substitute the present Preliminary Amendment therefor.

Prior to examination, Applicant respectfully requests that the above-identified application be amended as follows:

IN THE SPECIFICATION:

Please replace the following paragraphs with the following rewritten paragraphs. The changes are shown explicitly in the attached "Version with Markings to Show Changes Made."

Please replace the paragraph beginning on page 1 at line 23 with the following rewritten paragraph:

We have now found that GnRH-II has an important role in the function of a number of organs. For example, it influences osteogenesis and it modulates the proliferation of prostatic epithelial cells. Accordingly, we have considered the means by which this agent and its analogues might usefully be delivered in a clinical situation, and it is an object of the present invention to provide suitable formulations for achieving this purpose. The formulations according to the present invention rely on the use of a